Pfizer addressed questions about its COVID-19 vaccines, reaffirming they met regulatory standards while acknowledging ongoing data collection after rollout. The company said vaccines were developed quickly due to the global emergency, using large trials and post-authorization monitoring, a common practice under emergency-use frameworks.
